222 related articles for article (PubMed ID: 16670072)
1. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
[TBL] [Abstract][Full Text] [Related]
2. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
4. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
7. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
8. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia.
Raghavachar A; Ganser A; Freund M; Heimpel H; Herrmann F; Schrezenmeier H
Cytokines Mol Ther; 1996 Dec; 2(4):215-23. PubMed ID: 9384707
[TBL] [Abstract][Full Text] [Related]
9. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
Chen SC; Jiang B; Da WM; Gong M; Guan M
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
[TBL] [Abstract][Full Text] [Related]
10. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
11. Successful immunosuppressive therapy for a child with Myelodysplastic syndrome.
Orimoto M; Maeda M; Cai LZ; Hayakawa J; Ueda T; Migita M; Asano T
Med Pediatr Oncol; 2003 May; 40(5):334-5. PubMed ID: 12652627
[No Abstract] [Full Text] [Related]
12. [Cyclosporine A based therapy for myelodysplastic syndrome].
Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
[TBL] [Abstract][Full Text] [Related]
13. Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts.
Tamayose K; Sugimoto K; Ando M; Oshimi K
Blood; 2001 Apr; 97(8):2524. PubMed ID: 11307772
[No Abstract] [Full Text] [Related]
14. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia.
Zhang F; Zhang L; Jing L; Zhou K; Wang H; Peng G; Li Y; Li Y; Li J; Ye L; Shi L; Fan H; Zhao X; Chu Y; Hao Y; Wang J
Exp Hematol; 2013 Apr; 41(4):328-34. PubMed ID: 23313080
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myelodysplastic syndrome with cyclosporin A.
Chen S; Jiang B; Da W; Gong M; Guan M
Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of aplastic anemia with anti-thymocyte globulin and cyclosporine].
Ohnishi S; Nakagawa M; Kobayashi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Kasai M
Rinsho Ketsueki; 1998 Sep; 39(9):640-4. PubMed ID: 9796396
[TBL] [Abstract][Full Text] [Related]
18. Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine.
He G; Zhang X; Wu D; Sun A; Wang X
Pediatr Blood Cancer; 2011 Jul; 56(7):1133-5. PubMed ID: 21488160
[TBL] [Abstract][Full Text] [Related]
19. Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99).
Hasegawa D; Manabe A; Yagasaki H; Ohtsuka Y; Inoue M; Kikuchi A; Ohara A; Tsuchida M; Kojima S; Nakahata T;
Pediatr Blood Cancer; 2009 Dec; 53(6):1011-5. PubMed ID: 19499580
[TBL] [Abstract][Full Text] [Related]
20. Outcome of children with aplastic anemia treated with immunosuppressive therapy.
Pongtanakul B; Das PK; Charpentier K; Dror Y
Pediatr Blood Cancer; 2008 Jan; 50(1):52-7. PubMed ID: 17941069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
